Abstract
Objective To investigate the role of soluble triggering receptor expressed on myeloid cells-l(sTREM-1)in the diagnosis of infectious pneumonia. Methods Forty-two patients with infectious pneumonia(including 27 severe pneumonia patients and 15 non-severe pneumonia patients)and 19 patients with noninfectious interstitial lung diseases(ILD) were enrolled in the study. Nine healthy volunteers were recruited as controls, sTREM-1, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6 in.bronchoalveolar lavage fluid (BALF)and plasma were measured by a solid-phase enzyme-linked immunosorbent assay. Results ① sTREM-1 levels in BALF of severe pneumonia group and non-severe pneumonia group were higher than that in normal control group, (50. 27±18. 73)ng/L,(42. 83± 15.49)ng/Lvs (20. 58±6.92) ng/L(all P <0. 01). There was no statistical significance between ILD group[(22.77±5.90) ng/L]and normal control group. ② sTREM-1 level in plasma of severe pneumonia group was higher than that in non-severe pneumonia group, ( 76.36 ± 36.06 ) ng/L vs ( 19.46 ± 7, 73 )ng/ L ( P < 0.01 ).sTREM-1 level in plasma of non-severe pneumonia group was higher than that in ILD group and normal control group,(19.46 ± 7.73) ng/L vs (3. 42 ± 1.89) ng/L, (3.53 ± 1.53) ng/L( P <0.01), ③TNF-αand IL-6 in BALF and plasma of severe pneumonia group were higher than those in non-severe pneumonia group and ILD group(all P <0.01). TNF-α and IL-6 in BALF and plasma of non-severe pneumonia group and ILD group were higher than those in normal control group(all P <0.05). IL-1β levels in BALF of severe pneumonia group, non-severe pneumonia group and ILD group were higher than that in normal control group( P < 0.05 or P < 0.01 ). Conclusions sTREM-1 ean be a beneficial biomarker in the diagnosis of infectious pneumonia.and the assay of sTREM-1 in BALF and plasma can help evaluate the severity of infection. Key words: Soluble triggering receptor expressed on myeloid cells-1; Severe pneumonia; Interstitial lung diseases; Bronchoalveolar lavage fluid; Proinflammatory cytokines
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.